APYX vs ZBH
APYX: Apyx Medical provides advanced helium plasma-based surgical technology for cosmetic body contouring and hospital-based electrosurgical procedures. ZBH: A global leader in musculoskeletal healthcare, providing a comprehensive portfolio of reconstructive implants, sports medicine, and trauma technologies to restore patient mobility.
Side-by-side fundamentals
| Metric | APYX | ZBH | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $3.83 | $89.65 | |
| Market cap as of 2026-07-24 | $163M | $17.4B | |
| P/E as of 2026-07-24 | n/a | 22.90 | |
| PEG as of 2026-07-24 | n/a | 4.19 | |
| Net margin as of 2026-07-24 | -16.4% | +9.1% | ZBH higher |
| Gross margin as of 2026-07-24 | +63.1% | +70.0% | ZBH higher |
| Operating margin as of 2026-07-24 | -7.7% | +14.0% | ZBH higher |
| ROE as of 2026-07-24 | -90.6% | +6.0% | ZBH higher |
| ROA as of 2026-07-24 | -14.9% | +3.3% | ZBH higher |
| Debt / equity as of 2026-07-24 | 2.74 | 0.59 | ZBH lower |
| Revenue growth (YoY) as of 2026-07-24 | +18.2% | +9.2% | APYX higher |
| Revenue CAGR (3y) SEC XBRL | +5.9% | +5.9% | Tie |
| Dividend yield as of 2026-07-24 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-24 | 1.40 | 0.47 | |
| 1-year return as of 2026-07-23 close | +73.8% | -7.9% | APYX higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.